



The CCS is committed to preserving the scientific integrity of its Guidelines and Position Statements through transparency and management of potential conflicts of interest. All panel members must disclose all relationships with industry whether relevant to the guideline topic or not and potential conflicts are reviewed and assessed by the co-chairs and the CCS Guideline Committee. While the goal is to have the majority of a writing panel have no potential conflicts, this is not always feasible in today's medical landscape. When a potential conflict exists, the affected member must recuse during the formal consensus voting process. Below is a list of all disclosures for the APT panel, regardless of relevance to the 2018 APT Guideline Update. For more information on the CCS Guideline Development process, please visit www.ccs.ca.

Member	Affiliations with commercial organizations within the previous two years that may have a direct or indirect connection to the content of this guideline		
	Consulting fees/ Honoraria	Clinical Trials	Other financial benefit
Primary Panel			
Shamir Mehta	AstraZeneca, Bayer	AstraZeneca, Boston Scientific	
Jean-Francois Tanguay	Abbott Vascular, AstraZeneca, Bayer, Boehringer Ingelheim, GlaxoSmithKline, Novartis, Servier	Abbott Vascular, GlaxoSmithKline, Novartis	
John Mancini	Amgen, AstraZeneca, Boehringer Ingelheim / Eli Lilly Alliance, Merck, Novartis, NovoNordisk, Sanofi, Servier, Esperion		
Joseph Abunassar			
Margaret Ackman			
Kevin Bainey	Abbott Vascular, AstraZeneca, Bayer, BMS Pfizer		
Alan D. Bell	Amgen, AstraZeneca, Bayer, BMS Pfizer, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi-Sankyo, Janssen, NovoNordisk, Servier	AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Janssen, Eli Lilly	
John A. Cairns	Bayer, BMS Pfizer, Servier, St. Jude Medical	AstraZeneca, Boston Scientific	
Warren J. Cantor	AstraZeneca, Bayer		
Raymond Cartier			
James D. Douketis	Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Janssen, Sanofi		
Patrick Lawler			
Marie Lordkipanidzé			
Guillaume Marquis-Gravel			
Sean McMurtry			
Simon D. Robinson	AstraZeneca, Bayer	AstraZeneca, Bayer, Novartis, Sanofi, Esperion, Medinol	
Matthew Sibbald			
Derek So	Abbott Canada, AstraZeneca, St. Jude Medical	Eli Lilly, Spartan Biosciences	



Member	Affiliations with commercial organizations within the previous two years that may have a direct or indirect connection to the content of this guideline		
	Consulting fees/ Honoraria	Clinical Trials	Other financial benefit
Jacob A. Udell	Amgen, AstraZeneca, Boehringer Ingelheim / Eli Lilly Alliance, Janssen, Merck, Novartis, Servier, Sanofi Pasteur		
Sean van Diepen			
Subodh Verma	Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Eli Lilly, Janssen, Merck, Novartis, Abbott Vascular, sanofi-aventis, Valeant	AstraZeneca, Valeant	
Graham C. Wong	AstraZeneca, Bayer		
Secondary Panel			
Paul Armstrong	AstraZeneca, Bayer, Eli Lilly, Merck, Novartis, Mast Therapeutics, Inc.; Cardiome Pharma Corp.; Axio/Orexigen	Merck, Sanofi, CSL Limited	
Akshay Bagai	AstraZeneca, Bayer		
Claudia Bucci	AstraZeneca, Bayer, Boehringer Ingelheim, Servier		
Jean-Pierre Déry	Amgen, AstraZeneca, Bayer, BMS Pfizer, Boehringer Ingelheim, Boehringer Ingelheim / Eli Lilly Alliance, Eli Lilly, Janssen, NovoNordisk, Sanofi, Servier	Sanofi	
Jean G. Diodati	AstraZeneca, Eli Lilly	Eli Lilly	
Jocelyn Dupuis	Bayer, ProMetic Life Sciences		Administrator of PulmoScience Inc. 3 US and European Patents for "Use of adrenomedullin derivatives for imaging and therapy"
David Fitchett	Amgen, AstraZeneca, Boehringer Ingelheim / Eli Lilly Alliance, Bristol-Myers Squibb, Merck, Novartis, NovoNordisk		
Michael P. Love	AstraZeneca, Bayer	Amgen, AstraZeneca, Bristol-Myers Squibb, BIONICS trial (Medinol sponsor)	
Robert Welsh	Amgen, AstraZeneca, Bayer, BMS Pfizer, Boehringer Ingelheim / Eli Lilly Alliance	Abbott Vascular, Amgen, AstraZeneca, Bayer, BMS Pfizer, Boehringer Ingelheim, Janssen	